A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard
First-Line Therapy


Brief Summary

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
Principal Investigator
Randolph Hecht
  • TRIO-US - Bakersfield
  • TRIO-US - Redondo Beach
  • TRIO-US - Sylmar
  • TRIO-US - Whittier